During the past decade, SI Institute of the pediatrics, obstetrics and gynecology conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "SI Institute of the pediatrics, obstetrics and gynecology" are "Hepatitis B, Chronic" (1 trials) and "Pediatric Immuno-Tolerant Chronic Hepatitis B" (1 trials). Many other conditions were trialed in "SI Institute of the pediatrics, obstetrics and gynecology" in a lesser frequency.

Most popular intervention types in "SI Institute of the pediatrics, obstetrics and gynecology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Entecavir" (1 trials), "Lamivudine" (1 trials), "Pegylated Interferon Alfa-2A" (1 trials) and "peginterferon alfa-2a [Pegasys]" (1 trials). Other intervention names were less common.

The vast majority of trials in "SI Institute of the pediatrics, obstetrics and gynecology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "SI Institute of the pediatrics, obstetrics and gynecology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in SI Institute of the pediatrics, obstetrics and gynecology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in SI Institute of the pediatrics, obstetrics and gynecology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".